Browsing Tag
drug development
17 posts
Why BIOX-101 might succeed where decades of stroke research have struggled
Can BIOX-101 reshape stroke treatment timelines? Discover how Bioxodes SA’s strategy could accelerate approvals and change neurovascular care.
Verana Health and Guardant Health link genomics and real-world data to accelerate precision oncology drug
Verana Health and Guardant Health (GH) combine EHR and genomic data to accelerate oncology drug development. Read the full strategic analysis.
Curi Bio and Battelle partner to scale human-relevant neuromuscular testing platforms as FDA shifts toward animal-free drug development
Curi Bio and Battelle announce strategic partnership to commercialize neuromuscular junction testing technology, positioning for regulatory shift toward human-relevant drug development methods.
Clinical trial site selection reimagined: PSI CRO deploys Arango-powered SYNETIC to eliminate $30,000 site failures
PSI CRO reduced clinical trial site selection from 6 weeks to minutes using SYNETIC on the Arango AI platform. Find out what this means for CRO competition. Read more.
Can Atombeat and BioDuro’s trillion-compound AI engine transform peptide drug discovery in 2025?
Find out how Atombeat and BioDuro are using AI to revolutionize peptide drug discovery with faster timelines and lower R&D costs.
Triastek’s 3D-printed D23 tablet shows strong clinical results for IgAN treatment
Triastek has reported promising clinical results for its 3D-printed drug delivery product, D23 (Budesonide Ileum Targeted Tablets), which…
Granules India to acquire Senn Chemicals to expand CDMO business
Granules India Limited (BSE: 532482, NSE: GRANULES) has announced a strategic acquisition of Senn Chemicals AG, a Switzerland-based…
Cosette Pharmaceuticals to acquire Mayne Pharma in $430m deal, strengthening women’s health and dermatology portfolio
Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group Limited, a move that will significantly…
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
Could this startup have the cure for obesity? Meet Pep2Tango Therapeutics!
Versant Ventures has introduced Pep2Tango Therapeutics Inc., a biotechnology startup dedicated to pioneering next-generation therapies for weight loss.…